• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
CDMO Services in India CDMO Services in India

CDMO Services in India

About our Bangalore Facility

Our drug R&D facility based out of Bangalore, India is spread across 17 acres and has a lab space of 1,00,000 sq. ft. and has a legacy of +20 years. This facility has state-of-the-art labs to carry out research and development activities related to small molecules such as peptides, PROTACs, carbohydrates, mPEGs, oligonucleotides, etc.

Contact Us
Bangalore Facility

About our Hyderabad Facility

Our integrated drug R&D center based in Hyderabad, India is spread across 2,60,000 sq. ft. and is capable of handling small and large molecules. The facility has a legacy of +20 years and was audited by FDA in 2017. This facility has state-of-the-art labs to carry out activities related to drug discovery, development and manufacturing.

We have CTO-1, 2 and 3 facilities at our Hyderabad site for manufacturing of APIs and High Potent Active Ingredients (HPAIs).

Contact Us

About our Visakhapatnam Facility

Our CTO-6 and CTO-SEZ manufacturing facilities based in Visakhapatnam, India are spread across 40,07,520 Sq. ft. and 51,83,640 Sq. ft. respectively. We carry out peptide synthesis and manufacturing of APIs (non-sterile), Intermediates and High Potent Active Ingredients (HPAIs) at these facilities. At Visakhapatnam, we have state-of-the-art US FDA and EU-approved pilot & production manufacturing facility, CTO-6 PU-02 for formulations scale-up where we offer clinical & commercial batches. Our Visakhapatnam facility is inspected and approved by major regulatory agencies.

Contact Us
Visakhapatnam

Why Aurigene Services?

18 years of experience

Experience gained from 100+ discovery programmes

World-class infrastructure

Track record of delivering 8+ IND candidates

Flexible working models

Quick turnaround time

Capabilities to apply multiple modalities

Seamless integration capabilities with Biology as well as CDMO services

Integrated project management

Expertise in various therapeutic modalities

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Services

Aurigene Pharmaceutical Services Limited is a leading contract research, development and manufacturing organization (CDMO) providing end-to-end solutions. With a strong legacy of services in discovery, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide.

resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack